Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557842 · ClinicalTrials.gov registry record · Phase 4
Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators
A Phase 4 study, sponsored by Biosense Webster.
- Terminated
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT01557842 is a Phase 4 study that was terminated before completion, run by Biosense Webster. The registered enrollment target is 15 participants.
The verdict
NCT01557842, a Phase 4 study, was terminated before completion, sponsored by Biosense Webster.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if early ablation (i.e., ablation of ventricular tachycardia in patients with infrequent VT episodes) is more effective than medical therapy alone for the treatment of ischemic ventricular tachycardia in patients with Implantable Cardioverter Defibrillators (ICDs) who continue to have episodes of ventricular tachycardia despite drug therapy.
Interventions
- DEVICE Catheter Ablation
- DRUG Drug Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-06-01 |
| Est. Completion | 2014-03-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01557842
The ClinicalTrials.gov registry entry for NCT01557842 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Catheter Ablation is the first listed.
NCT01557842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01557842 about?
NCT01557842 is a clinical study titled "Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators". The purpose of this study is to determine if early ablation (i.e., ablation of ventricular tachycardia in patients with infrequent VT episodes) is more effective than medical therapy alone for the treatment of ischemic ventricular tachycardia in patients with Implantable Cardioverter Defibrillators ...
What is the current status of trial NCT01557842?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2012-06-01. Estimated completion is 2014-03-19.
What interventions are being tested in trial NCT01557842?
The interventions under investigation include: Catheter Ablation (DEVICE), Drug Treatment (DRUG).
Who is sponsoring clinical trial NCT01557842?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.